James and Esther King Biomedical Research Program   Report issue

Foundation Phase 1 Phase 2
Founded: Tallahassee FL United States (2018)

Organization Overview

First Clinical Trial
2018
NCT01625260
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

James and Esther King Biomedical Research Program

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Lung Diseases (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasms, Squamous Cell (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Tobacco Use Disorder (Phase 1)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 12